Figure 3

Survival charts of the reclassified cytogenetic groups. Patients with poor clone as minor had comparable survival with patients with sole del 13q or without any cytogenetic aberration, while patients with concomitant trisomy 12 and t(14q32) and del 13q had adverse survival similar to patients with one poor clone or poor clone as major, in aspect of time to first therapy (a), progression free survival (b) and overall survival (c).